Bio Green Med Solution, Inc. — Director's Dealing 2019

Jan 7, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cyclacel Pharmaceuticals, Inc. (CYCC)
CIK: 0001130166
Period of Report: 2019-01-03

Reporting Person: Rombotis Spiro George (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-04	Option	$0.71	A	508198	Acquired	2029-01-04	Common Stock (508198)	Direct
2019-01-03	Option	$1.74	A	15625	Acquired	2027-12-29	Common Stock (15625)	Direct
2019-01-03	Option	$1.56	A	14375	Acquired	2028-02-22	Common Stock (14375)	Direct

Footnotes

F1: These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis.

F2: These securities were granted as part of the Issuer's annual compensation review to executive officers.

F3: On December 29, 2017, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 15,625 shares.

F4: On February 22, 2018, Spiro Rombotis was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 14,375 shares.